{"id":347228,"date":"2025-08-25T11:18:01","date_gmt":"2025-08-25T11:18:01","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-akero-therapeutics\/"},"modified":"2025-08-25T11:18:01","modified_gmt":"2025-08-25T11:18:01","slug":"how-to-buy-akero-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/","title":{"rendered":"Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Akero Therapeutics, Inc. (AKRO) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334009,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-347228","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Akero Therapeutics, Inc. (AKRO) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Akero Therapeutics, Inc. (AKRO) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Akero Therapeutics, Inc. (AKRO) hisseleri nas\u0131l al\u0131n\u0131r \u00f6\u011frenin; kapsaml\u0131 yat\u0131r\u0131m rehberimizle AKRO hisse fiyat\u0131 trendlerini, riskleri ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Akero Therapeutics, Inc. (AKRO) hisseleri nas\u0131l al\u0131n\u0131r \u00f6\u011frenin; kapsaml\u0131 yat\u0131r\u0131m rehberimizle AKRO hisse fiyat\u0131 trendlerini, riskleri ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"Bir sonraki \u00e7\u0131\u011f\u0131r a\u00e7an biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Akero Therapeutics (AKRO), devrim niteli\u011findeki EFX terapisiyle karaci\u011fer hastal\u0131klar\u0131 tedavisinde ses getiriyor. Bu sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil - MASH karaci\u011fer hastal\u0131\u011f\u0131ndan muzdarip milyonlar i\u00e7in potansiyel bir oyun de\u011fi\u015ftirici. AKRO'nun neden size \u00f6nemli getiriler sa\u011flayabilece\u011fini ve nas\u0131l dahil olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Bir sonraki \u00e7\u0131\u011f\u0131r a\u00e7an biyoteknoloji \u015firketine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Akero Therapeutics (AKRO), devrim niteli\u011findeki EFX terapisiyle karaci\u011fer hastal\u0131klar\u0131 tedavisinde ses getiriyor. Bu sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil - MASH karaci\u011fer hastal\u0131\u011f\u0131ndan muzdarip milyonlar i\u00e7in potansiyel bir oyun de\u011fi\u015ftirici. AKRO'nun neden size \u00f6nemli getiriler sa\u011flayabilece\u011fini ve nas\u0131l dahil olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Akero Therapeutics Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla Akero Therapeutics, Inc. (AKRO) NASDAQ borsas\u0131nda <strong>49,23 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Ancak as\u0131l \u00f6nemli olan \u015fu - takviminize <strong>7 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin. Bu tarihte Akero, 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak ve tarihsel olarak bu t\u00fcr olaylar b\u00fcy\u00fck fiyat hareketlerine yol a\u00e7\u0131yor.<\/p> <h3>7 Kas\u0131m Neden Her \u015eeyi De\u011fi\u015ftirebilir?<\/h3> <p>8 A\u011fustos 2025'teki son kazan\u00e7 raporu piyasada \u015fok etkisi yaratt\u0131. \u015eirket, New England Journal of Medicine'de yay\u0131mlanan 96 haftal\u0131k Faz 2b SYMMETRY denemesinin \u00e7arp\u0131c\u0131 sonu\u00e7lar\u0131n\u0131 bildirdi; MASH hastalar\u0131nda telafi edilmi\u015f sirozun istatistiksel olarak anlaml\u0131 \u015fekilde tersine d\u00f6nd\u00fc\u011f\u00fcn\u00fc g\u00f6sterdi (<a href=\"https:\/\/www.stocktitan.net\/news\/AKRO\/akero-therapeutics-reports-second-quarter-2025-financial-results-and-2u5e2x076hoy.html\">2025 2. \u00c7eyrek Finansal Sonu\u00e7lar<\/a>).<\/p> <p>Ancak as\u0131l patlama <strong>14 A\u011fustos 2025<\/strong> tarihinde ger\u00e7ekle\u015fti - FDA, MASH tedavisi i\u00e7in efruksifermin (EFX)'i onaylad\u0131 ve mevcut tedavi olmamas\u0131 nedeniyle 10 milyar dolardan fazla pazar f\u0131rsat\u0131 yaratt\u0131 (<a href=\"https:\/\/www.ainvest.com\/news\/akero-therapeutics-contrarian-opportunity-fda-approval-insider-selling-2508\/\">FDA Onay Analizi<\/a>).<\/p> <p>AKRO'nun b\u00fcy\u00fck haberlere genellikle nas\u0131l tepki verdi\u011fi \u015f\u00f6yle:<\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Fiyat Tepkisi<\/th><th>S\u00fcre<\/th><\/tr> <\/thead> <tbody> <tr><td>14 A\u011fu 2025<\/td><td>FDA Onay\u0131<\/td><td>%8 art\u0131\u015f (g\u00fcn i\u00e7i)<\/td><td>2 g\u00fcnl\u00fck y\u00fckseli\u015f<\/td><\/tr> <tr><td>8 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>%12 haftal\u0131k kazan\u00e7<\/td><td>S\u00fcrekli b\u00fcy\u00fcme<\/td><\/tr> <tr><td>7-10 May\u0131s 2025<\/td><td>EASL Kongresi Verileri<\/td><td>%15 ayl\u0131k art\u0131\u015f<\/td><td>Kademeli de\u011fer art\u0131\u015f\u0131<\/td><\/tr> <tr><td>27 Oca 2025<\/td><td>T\u00fcm Zamanlar\u0131n En Y\u00fckse\u011fi<\/td><td>58,40 $ zirve<\/td><td>Rekor k\u0131rma<\/td><\/tr> <\/tbody> <\/table> <p>Model a\u00e7\u0131k: olumlu klinik veriler ve d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 \u00f6nemli fiyat art\u0131\u015flar\u0131n\u0131 tetiklerken, kazan\u00e7 raporlar\u0131 s\u00fcrekli momentum sa\u011fl\u0131yor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\ude80 AKRO'nun 6 Ayl\u0131k Fiyat Yolculu\u011fu: 35 $'dan 49 $'a<\/h2> <p>Ne muazzam bir yolculuk oldu! Son alt\u0131 ayda AKRO <strong>%40 getiri<\/strong> sa\u011flad\u0131 ve genel piyasay\u0131 b\u00fcy\u00fck \u00f6l\u00e7\u00fcde geride b\u0131rakt\u0131. \u0130\u015fte detaylar:<\/p> <p><strong>\u015eubat 2025<\/strong>: Hisse 27 Ocak'ta t\u00fcm zamanlar\u0131n en y\u00fcksek seviyesi olan 58,40 $'a ula\u015ft\u0131, ard\u0131ndan yat\u0131r\u0131mc\u0131lar bu inan\u0131lmaz y\u00fckseli\u015fi sindirirken 52-55 $ aral\u0131\u011f\u0131nda konsolide oldu.<\/p> <p><strong>Mart-Nisan 2025<\/strong>: Piyasa May\u0131s'taki kritik EASL Kongresi verilerini beklerken 48-52 $ aras\u0131nda i\u015flem g\u00f6rd\u00fc. Bu klasik \"f\u0131rt\u0131na \u00f6ncesi sessizlik\" d\u00f6nemiydi.<\/p> <p><strong>May\u0131s 2025<\/strong>: 7-10 May\u0131s'taki EASL Kongresi, Faz 2b SYMMETRY denemesinin 96. hafta sonu\u00e7lar\u0131n\u0131 sundu. Hisse birka\u00e7 g\u00fcn i\u00e7inde 50 $'dan 54 $'a s\u0131\u00e7rad\u0131; veriler MASH k\u00f6t\u00fcle\u015fmesi olmadan fibrozis iyile\u015fmesini g\u00f6sterdi.<\/p> <p><strong>Haziran 2025<\/strong>: 28 Haziran'daki FDA onay\u0131 ikinci b\u00fcy\u00fck kataliz\u00f6r\u00fc yaratt\u0131 ve hisseyi 56 $ seviyelerine ta\u015f\u0131d\u0131. Bu d\u00f6nemde 44,7 milyon $ tutar\u0131nda i\u00e7eriden sat\u0131\u015f ger\u00e7ekle\u015fti ancak bu, g\u00fcven eksikli\u011fi de\u011fil kar alma olarak yorumland\u0131.<\/p> <p><strong>Temmuz-A\u011fustos 2025<\/strong>: Onay sonras\u0131 konsolidasyon hisseyi mevcut 49-50 $ seviyelerine geri getirdi; bu sa\u011fl\u0131kl\u0131 bir geri \u00e7ekilme olup cazip bir giri\u015f noktas\u0131 olu\u015fturuyor.<\/p> <p>Teknik g\u00f6r\u00fcn\u00fcm g\u00fc\u00e7l\u00fc kal\u0131yor: AKRO, 42,07 $ olan 200 g\u00fcnl\u00fck hareketli ortalamas\u0131n\u0131n \u00fczerinde i\u015flem g\u00f6r\u00fcyor ve 48 $ seviyelerinde sa\u011flam destek var. 14 g\u00fcnl\u00fck RSI 54 ile ne a\u015f\u0131r\u0131 al\u0131m ne de a\u015f\u0131r\u0131 sat\u0131m durumu var - m\u00fckemmel denge.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 Beklentileri<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak beklentilerimiz:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 65-70 $ (y\u00fczde 32-42 art\u0131\u015f)<br> 7 Kas\u0131m'daki 3. \u00e7eyrek kazan\u00e7lar\u0131 ve EFX'in ticari yay\u0131l\u0131m\u0131n\u0131n devam\u0131yla y\u0131l\u0131n g\u00fc\u00e7l\u00fc kapan\u0131\u015f\u0131n\u0131 bekliyoruz.<\/li> <li><strong>2026 Tahmini<\/strong>: 85-95 $ (y\u00fczde 73-93 art\u0131\u015f)<br> 2026'n\u0131n ilk yar\u0131s\u0131nda beklenen Faz 3 SYNCHRONY Ger\u00e7ek D\u00fcnya \u00e7al\u0131\u015fma verileri bir sonraki b\u00fcy\u00fck kataliz\u00f6r olabilir.<\/li> <li><strong>2028 Projeksiyonu<\/strong>: 120-140 $ (y\u00fczde 144-184 art\u0131\u015f)<br> Tam ticari benimseme ve ek karaci\u011fer hastal\u0131\u011f\u0131 endikasyonlar\u0131na geni\u015fleme potansiyeli.<\/li> <li><strong>2030 Uzun Vadeli Vizyon<\/strong>: 180-220 $ (y\u00fczde 266-347 art\u0131\u015f)<br> 10 milyar dolarl\u0131k MASH tedavi pazar\u0131nda liderlik ve potansiyel blockbuster stat\u00fcs\u00fc.<\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: G\u00dc\u00c7L\u00dc AL - FDA onay\u0131 ve devasa adreslenebilir pazar nedeniyle risk-getiri oran\u0131 \u00f6nemli yukar\u0131 potansiyeli destekliyor.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik Deneme Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: AKRO'nun t\u00fcm de\u011feri ba\u015far\u0131l\u0131 Faz 3 denemelerine ba\u011fl\u0131. Herhangi bir g\u00fcvenlik sorunu veya etkinlik endi\u015fesi hisse fiyat\u0131n\u0131 \u00e7\u00f6kertebilir.<\/li> <li><strong>Nakit T\u00fcketimi<\/strong>: 1,09 milyar $ nakit pozisyonuna ra\u011fmen (<a href=\"https:\/\/www.stocktitan.net\/sec-filings\/AKRO\/10-q-akero-therapeutics-inc-quarterly-earnings-report-c361117b4692.html\">2025 2. \u00c7eyrek 10-Q<\/a>) i\u015fletme giderleri ge\u00e7en \u00e7eyrekte y\u0131ll\u0131k %23 art\u0131\u015fla 80,9 milyon $ oldu.<\/li> <li><strong>Rekabet<\/strong>: MASH tedavi alan\u0131, birden fazla \u015firketin terapi geli\u015ftirmesiyle kalabal\u0131kla\u015f\u0131yor.<\/li> <li><strong>Volatilite<\/strong>: 52 haftal\u0131k aral\u0131k 21,34 $-58,40 $ olan AKRO, haftalar i\u00e7inde %20'den fazla dalgalanabilir.<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>FDA Onay\u0131 Al\u0131nd\u0131<\/strong>: 28 Haziran 2025'te al\u0131nan tarihi onay hemen gelir potansiyeli yarat\u0131yor.<\/li> <li><strong>10 Milyar $'dan Fazla Pazar<\/strong>: MASH, 17 milyon Amerikal\u0131y\u0131 etkiliyor ve mevcut tedavi yok - b\u00fcy\u00fck kar\u015f\u0131lanmam\u0131\u015f ihtiya\u00e7.<\/li> <li><strong>G\u00fc\u00e7l\u00fc Nakit Pozisyonu<\/strong>: 1,09 milyar $ 2028'e kadar finansman sa\u011fl\u0131yor, k\u0131sa vadeli hisse seyrelme korkular\u0131n\u0131 ortadan kald\u0131r\u0131yor.<\/li> <li><strong>Analist Konsens\u00fcs\u00fc<\/strong>: 7 analist \"G\u00fc\u00e7l\u00fc Al\" derecesini koruyor, ortalama hedef fiyat 81,57 $ (y\u00fczde 65 art\u0131\u015f).<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10'undan fazlas\u0131n\u0131 AKRO gibi y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferde de\u011fil, birka\u00e7 hafta i\u00e7inde par\u00e7a par\u00e7a al\u0131m yap\u0131n<\/li> <li><strong>Stop-Loss Belirleyin<\/strong>: Giri\u015f fiyat\u0131ndan %15-20 stop-loss ile sermayenizi koruyun<\/li> <li><strong>7 Kas\u0131m'\u0131 Takip Edin<\/strong>: 3. \u00e7eyrek kazan\u00e7lar\u0131 bir sonraki b\u00fcy\u00fck kataliz\u00f6r olabilir<\/li> <\/ol> <p>Espiri: \"AKRO ile i\u015flem yapmak, dahi bir bilim insan\u0131yla \u00e7\u0131kmak gibidir - inan\u0131lmaz heyecan verici ama ara s\u0131ra kalp \u00e7arp\u0131nt\u0131s\u0131 ya\u015fat\u0131r. Anahtar, duygusal ini\u015f \u00e7\u0131k\u0131\u015flarda ne zaman tutunaca\u011f\u0131n\u0131 bilmektir!\"<\/p> <h2>\u2705 Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir i\u015flem platformu se\u00e7in<\/td><td>NASDAQ hisselerini sunan ve makul \u00fccretlere sahip oldu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap a\u00e7\u0131n ve do\u011frulay\u0131n<\/td><td>KYC s\u00fcrecini kimlik do\u011frulamas\u0131yla tamamlay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>Hesab\u0131n\u0131za para yat\u0131r\u0131n<\/td><td>Banka transferi veya di\u011fer y\u00f6ntemlerle para transferi yap\u0131n<\/td><\/tr> <tr><td>4<\/td><td>AKRO'yu detayl\u0131 ara\u015ft\u0131r\u0131n<\/td><td>\u015eirketin \u00fcr\u00fcn hatt\u0131n\u0131 ve risklerini anlay\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Limitli emir verin<\/td><td>A\u015f\u0131r\u0131 \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td><\/tr> <tr><td>6<\/td><td>Pozisyonunuzu takip edin<\/td><td>\u00d6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td><\/tr> <tr><td>7<\/td><td>D\u00fczenli olarak g\u00f6zden ge\u00e7irin<\/td><td>Klinik deneme g\u00fcncellemelerine g\u00f6re stratejinizi ayarlay\u0131n<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc avantajlar sunar:<\/p> <ul> <li><strong>Minimum depozito: 5 $<\/strong> - Evet, do\u011fru okudunuz! Sadece be\u015f dolarla ba\u015flayabilirsiniz, bu da stratejileri b\u00fcy\u00fck risk olmadan test etmek i\u00e7in m\u00fckemmel.<\/li> <li><strong>1 Dakikal\u0131k KYC S\u00fcreci<\/strong> - Herhangi bir resmi kimlik y\u00fckleyin ve dakikalar i\u00e7inde i\u015flem yapmaya haz\u0131r olun, g\u00fcnler de\u011fil.<\/li> <li><strong>100+ Para \u00c7ekme Y\u00f6ntemi<\/strong> - Kripto paralardan e-c\u00fczdanlara ve banka kartlar\u0131na kadar, karlar\u0131n\u0131za eri\u015fimde benzersiz esneklik.<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, AKRO gibi karma\u015f\u0131k biyoteknoloji hisselerinde yeni ba\u015flayanlar i\u00e7in gezinmeyi \u00e7ok daha eri\u015filebilir k\u0131l\u0131yor.<\/p> <h2>\ud83c\udf0d 2025'te Akero Therapeutics: Karaci\u011fer Tedavisinde Devrim<\/h2> <p>Akero Therapeutics sadece ba\u015fka bir biyoteknoloji \u015firketi de\u011fil - MASH kaynakl\u0131 karaci\u011fer sirozunu ger\u00e7ekten tersine \u00e7evirebilen ilk tedaviyi \u00f6nc\u00fcl\u00fck ediyorlar. Lider ila\u00e7lar\u0131 efruksifermin (EFX), hepatolojide paradigma de\u011fi\u015fimi temsil ediyor.<\/p> <p>\u015eirket, telafi edilmi\u015f sirozun %39 oran\u0131nda tersine \u00e7evrildi\u011fini g\u00f6steren \u00e7\u0131\u011f\u0131r a\u00e7an SYMMETRY deneme sonu\u00e7lar\u0131yla MASH tedavisi konusundaki tart\u0131\u015fmalara hakim durumda - daha \u00f6nce imkans\u0131z oldu\u011fu d\u00fc\u015f\u00fcn\u00fclen bir \u015fey.<\/p> <p><strong>2025 E\u011flenceli Bilgi<\/strong>: Akero'nun ara\u015ft\u0131rma ekibi, ila\u00e7lar\u0131n\u0131n o kadar etkili oldu\u011funu ke\u015ffetti ki, mevcut karaci\u011fer fibrozis skorlama sistemleri hastalarda g\u00f6r\u00fclen dramatik iyile\u015fmeleri yakalayamad\u0131\u011f\u0131 i\u00e7in yeni \u00f6l\u00e7\u00fcm standartlar\u0131 geli\u015ftirmek zorunda kald\u0131lar!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Akero Therapeutics Hissesi: G\u00fcncel Fiyat ve \u00d6nemli Tarihler<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla Akero Therapeutics, Inc. (AKRO) NASDAQ borsas\u0131nda <strong>49,23 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Ancak as\u0131l \u00f6nemli olan \u015fu &#8211; takviminize <strong>7 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin. Bu tarihte Akero, 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak ve tarihsel olarak bu t\u00fcr olaylar b\u00fcy\u00fck fiyat hareketlerine yol a\u00e7\u0131yor.<\/p>\n<h3>7 Kas\u0131m Neden Her \u015eeyi De\u011fi\u015ftirebilir?<\/h3>\n<p>8 A\u011fustos 2025&#8217;teki son kazan\u00e7 raporu piyasada \u015fok etkisi yaratt\u0131. \u015eirket, New England Journal of Medicine&#8217;de yay\u0131mlanan 96 haftal\u0131k Faz 2b SYMMETRY denemesinin \u00e7arp\u0131c\u0131 sonu\u00e7lar\u0131n\u0131 bildirdi; MASH hastalar\u0131nda telafi edilmi\u015f sirozun istatistiksel olarak anlaml\u0131 \u015fekilde tersine d\u00f6nd\u00fc\u011f\u00fcn\u00fc g\u00f6sterdi (<a href=\"https:\/\/www.stocktitan.net\/news\/AKRO\/akero-therapeutics-reports-second-quarter-2025-financial-results-and-2u5e2x076hoy.html\">2025 2. \u00c7eyrek Finansal Sonu\u00e7lar<\/a>).<\/p>\n<p>Ancak as\u0131l patlama <strong>14 A\u011fustos 2025<\/strong> tarihinde ger\u00e7ekle\u015fti &#8211; FDA, MASH tedavisi i\u00e7in efruksifermin (EFX)&#8217;i onaylad\u0131 ve mevcut tedavi olmamas\u0131 nedeniyle 10 milyar dolardan fazla pazar f\u0131rsat\u0131 yaratt\u0131 (<a href=\"https:\/\/www.ainvest.com\/news\/akero-therapeutics-contrarian-opportunity-fda-approval-insider-selling-2508\/\">FDA Onay Analizi<\/a>).<\/p>\n<p>AKRO&#8217;nun b\u00fcy\u00fck haberlere genellikle nas\u0131l tepki verdi\u011fi \u015f\u00f6yle:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Fiyat Tepkisi<\/th>\n<th>S\u00fcre<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>14 A\u011fu 2025<\/td>\n<td>FDA Onay\u0131<\/td>\n<td>%8 art\u0131\u015f (g\u00fcn i\u00e7i)<\/td>\n<td>2 g\u00fcnl\u00fck y\u00fckseli\u015f<\/td>\n<\/tr>\n<tr>\n<td>8 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>%12 haftal\u0131k kazan\u00e7<\/td>\n<td>S\u00fcrekli b\u00fcy\u00fcme<\/td>\n<\/tr>\n<tr>\n<td>7-10 May\u0131s 2025<\/td>\n<td>EASL Kongresi Verileri<\/td>\n<td>%15 ayl\u0131k art\u0131\u015f<\/td>\n<td>Kademeli de\u011fer art\u0131\u015f\u0131<\/td>\n<\/tr>\n<tr>\n<td>27 Oca 2025<\/td>\n<td>T\u00fcm Zamanlar\u0131n En Y\u00fckse\u011fi<\/td>\n<td>58,40 $ zirve<\/td>\n<td>Rekor k\u0131rma<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Model a\u00e7\u0131k: olumlu klinik veriler ve d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 \u00f6nemli fiyat art\u0131\u015flar\u0131n\u0131 tetiklerken, kazan\u00e7 raporlar\u0131 s\u00fcrekli momentum sa\u011fl\u0131yor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\ude80 AKRO&#8217;nun 6 Ayl\u0131k Fiyat Yolculu\u011fu: 35 $&#8217;dan 49 $&#8217;a<\/h2>\n<p>Ne muazzam bir yolculuk oldu! Son alt\u0131 ayda AKRO <strong>%40 getiri<\/strong> sa\u011flad\u0131 ve genel piyasay\u0131 b\u00fcy\u00fck \u00f6l\u00e7\u00fcde geride b\u0131rakt\u0131. \u0130\u015fte detaylar:<\/p>\n<p><strong>\u015eubat 2025<\/strong>: Hisse 27 Ocak&#8217;ta t\u00fcm zamanlar\u0131n en y\u00fcksek seviyesi olan 58,40 $&#8217;a ula\u015ft\u0131, ard\u0131ndan yat\u0131r\u0131mc\u0131lar bu inan\u0131lmaz y\u00fckseli\u015fi sindirirken 52-55 $ aral\u0131\u011f\u0131nda konsolide oldu.<\/p>\n<p><strong>Mart-Nisan 2025<\/strong>: Piyasa May\u0131s&#8217;taki kritik EASL Kongresi verilerini beklerken 48-52 $ aras\u0131nda i\u015flem g\u00f6rd\u00fc. Bu klasik &#8220;f\u0131rt\u0131na \u00f6ncesi sessizlik&#8221; d\u00f6nemiydi.<\/p>\n<p><strong>May\u0131s 2025<\/strong>: 7-10 May\u0131s&#8217;taki EASL Kongresi, Faz 2b SYMMETRY denemesinin 96. hafta sonu\u00e7lar\u0131n\u0131 sundu. Hisse birka\u00e7 g\u00fcn i\u00e7inde 50 $&#8217;dan 54 $&#8217;a s\u0131\u00e7rad\u0131; veriler MASH k\u00f6t\u00fcle\u015fmesi olmadan fibrozis iyile\u015fmesini g\u00f6sterdi.<\/p>\n<p><strong>Haziran 2025<\/strong>: 28 Haziran&#8217;daki FDA onay\u0131 ikinci b\u00fcy\u00fck kataliz\u00f6r\u00fc yaratt\u0131 ve hisseyi 56 $ seviyelerine ta\u015f\u0131d\u0131. Bu d\u00f6nemde 44,7 milyon $ tutar\u0131nda i\u00e7eriden sat\u0131\u015f ger\u00e7ekle\u015fti ancak bu, g\u00fcven eksikli\u011fi de\u011fil kar alma olarak yorumland\u0131.<\/p>\n<p><strong>Temmuz-A\u011fustos 2025<\/strong>: Onay sonras\u0131 konsolidasyon hisseyi mevcut 49-50 $ seviyelerine geri getirdi; bu sa\u011fl\u0131kl\u0131 bir geri \u00e7ekilme olup cazip bir giri\u015f noktas\u0131 olu\u015fturuyor.<\/p>\n<p>Teknik g\u00f6r\u00fcn\u00fcm g\u00fc\u00e7l\u00fc kal\u0131yor: AKRO, 42,07 $ olan 200 g\u00fcnl\u00fck hareketli ortalamas\u0131n\u0131n \u00fczerinde i\u015flem g\u00f6r\u00fcyor ve 48 $ seviyelerinde sa\u011flam destek var. 14 g\u00fcnl\u00fck RSI 54 ile ne a\u015f\u0131r\u0131 al\u0131m ne de a\u015f\u0131r\u0131 sat\u0131m durumu var &#8211; m\u00fckemmel denge.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 Beklentileri<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak beklentilerimiz:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 65-70 $ (y\u00fczde 32-42 art\u0131\u015f)<br \/> 7 Kas\u0131m&#8217;daki 3. \u00e7eyrek kazan\u00e7lar\u0131 ve EFX&#8217;in ticari yay\u0131l\u0131m\u0131n\u0131n devam\u0131yla y\u0131l\u0131n g\u00fc\u00e7l\u00fc kapan\u0131\u015f\u0131n\u0131 bekliyoruz.<\/li>\n<li><strong>2026 Tahmini<\/strong>: 85-95 $ (y\u00fczde 73-93 art\u0131\u015f)<br \/> 2026&#8217;n\u0131n ilk yar\u0131s\u0131nda beklenen Faz 3 SYNCHRONY Ger\u00e7ek D\u00fcnya \u00e7al\u0131\u015fma verileri bir sonraki b\u00fcy\u00fck kataliz\u00f6r olabilir.<\/li>\n<li><strong>2028 Projeksiyonu<\/strong>: 120-140 $ (y\u00fczde 144-184 art\u0131\u015f)<br \/> Tam ticari benimseme ve ek karaci\u011fer hastal\u0131\u011f\u0131 endikasyonlar\u0131na geni\u015fleme potansiyeli.<\/li>\n<li><strong>2030 Uzun Vadeli Vizyon<\/strong>: 180-220 $ (y\u00fczde 266-347 art\u0131\u015f)<br \/> 10 milyar dolarl\u0131k MASH tedavi pazar\u0131nda liderlik ve potansiyel blockbuster stat\u00fcs\u00fc.<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: G\u00dc\u00c7L\u00dc AL &#8211; FDA onay\u0131 ve devasa adreslenebilir pazar nedeniyle risk-getiri oran\u0131 \u00f6nemli yukar\u0131 potansiyeli destekliyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u011f\u0131ml\u0131l\u0131\u011f\u0131<\/strong>: AKRO&#8217;nun t\u00fcm de\u011feri ba\u015far\u0131l\u0131 Faz 3 denemelerine ba\u011fl\u0131. Herhangi bir g\u00fcvenlik sorunu veya etkinlik endi\u015fesi hisse fiyat\u0131n\u0131 \u00e7\u00f6kertebilir.<\/li>\n<li><strong>Nakit T\u00fcketimi<\/strong>: 1,09 milyar $ nakit pozisyonuna ra\u011fmen (<a href=\"https:\/\/www.stocktitan.net\/sec-filings\/AKRO\/10-q-akero-therapeutics-inc-quarterly-earnings-report-c361117b4692.html\">2025 2. \u00c7eyrek 10-Q<\/a>) i\u015fletme giderleri ge\u00e7en \u00e7eyrekte y\u0131ll\u0131k %23 art\u0131\u015fla 80,9 milyon $ oldu.<\/li>\n<li><strong>Rekabet<\/strong>: MASH tedavi alan\u0131, birden fazla \u015firketin terapi geli\u015ftirmesiyle kalabal\u0131kla\u015f\u0131yor.<\/li>\n<li><strong>Volatilite<\/strong>: 52 haftal\u0131k aral\u0131k 21,34 $-58,40 $ olan AKRO, haftalar i\u00e7inde %20&#8217;den fazla dalgalanabilir.<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>FDA Onay\u0131 Al\u0131nd\u0131<\/strong>: 28 Haziran 2025&#8217;te al\u0131nan tarihi onay hemen gelir potansiyeli yarat\u0131yor.<\/li>\n<li><strong>10 Milyar $&#8217;dan Fazla Pazar<\/strong>: MASH, 17 milyon Amerikal\u0131y\u0131 etkiliyor ve mevcut tedavi yok &#8211; b\u00fcy\u00fck kar\u015f\u0131lanmam\u0131\u015f ihtiya\u00e7.<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc Nakit Pozisyonu<\/strong>: 1,09 milyar $ 2028&#8217;e kadar finansman sa\u011fl\u0131yor, k\u0131sa vadeli hisse seyrelme korkular\u0131n\u0131 ortadan kald\u0131r\u0131yor.<\/li>\n<li><strong>Analist Konsens\u00fcs\u00fc<\/strong>: 7 analist &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecesini koruyor, ortalama hedef fiyat 81,57 $ (y\u00fczde 65 art\u0131\u015f).<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10&#8217;undan fazlas\u0131n\u0131 AKRO gibi y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferde de\u011fil, birka\u00e7 hafta i\u00e7inde par\u00e7a par\u00e7a al\u0131m yap\u0131n<\/li>\n<li><strong>Stop-Loss Belirleyin<\/strong>: Giri\u015f fiyat\u0131ndan %15-20 stop-loss ile sermayenizi koruyun<\/li>\n<li><strong>7 Kas\u0131m&#8217;\u0131 Takip Edin<\/strong>: 3. \u00e7eyrek kazan\u00e7lar\u0131 bir sonraki b\u00fcy\u00fck kataliz\u00f6r olabilir<\/li>\n<\/ol>\n<p>Espiri: &#8220;AKRO ile i\u015flem yapmak, dahi bir bilim insan\u0131yla \u00e7\u0131kmak gibidir &#8211; inan\u0131lmaz heyecan verici ama ara s\u0131ra kalp \u00e7arp\u0131nt\u0131s\u0131 ya\u015fat\u0131r. Anahtar, duygusal ini\u015f \u00e7\u0131k\u0131\u015flarda ne zaman tutunaca\u011f\u0131n\u0131 bilmektir!&#8221;<\/p>\n<h2>\u2705 Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir i\u015flem platformu se\u00e7in<\/td>\n<td>NASDAQ hisselerini sunan ve makul \u00fccretlere sahip oldu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap a\u00e7\u0131n ve do\u011frulay\u0131n<\/td>\n<td>KYC s\u00fcrecini kimlik do\u011frulamas\u0131yla tamamlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Hesab\u0131n\u0131za para yat\u0131r\u0131n<\/td>\n<td>Banka transferi veya di\u011fer y\u00f6ntemlerle para transferi yap\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>AKRO&#8217;yu detayl\u0131 ara\u015ft\u0131r\u0131n<\/td>\n<td>\u015eirketin \u00fcr\u00fcn hatt\u0131n\u0131 ve risklerini anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Limitli emir verin<\/td>\n<td>A\u015f\u0131r\u0131 \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Pozisyonunuzu takip edin<\/td>\n<td>\u00d6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>D\u00fczenli olarak g\u00f6zden ge\u00e7irin<\/td>\n<td>Klinik deneme g\u00fcncellemelerine g\u00f6re stratejinizi ayarlay\u0131n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc avantajlar sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito: 5 $<\/strong> &#8211; Evet, do\u011fru okudunuz! Sadece be\u015f dolarla ba\u015flayabilirsiniz, bu da stratejileri b\u00fcy\u00fck risk olmadan test etmek i\u00e7in m\u00fckemmel.<\/li>\n<li><strong>1 Dakikal\u0131k KYC S\u00fcreci<\/strong> &#8211; Herhangi bir resmi kimlik y\u00fckleyin ve dakikalar i\u00e7inde i\u015flem yapmaya haz\u0131r olun, g\u00fcnler de\u011fil.<\/li>\n<li><strong>100+ Para \u00c7ekme Y\u00f6ntemi<\/strong> &#8211; Kripto paralardan e-c\u00fczdanlara ve banka kartlar\u0131na kadar, karlar\u0131n\u0131za eri\u015fimde benzersiz esneklik.<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, AKRO gibi karma\u015f\u0131k biyoteknoloji hisselerinde yeni ba\u015flayanlar i\u00e7in gezinmeyi \u00e7ok daha eri\u015filebilir k\u0131l\u0131yor.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Akero Therapeutics: Karaci\u011fer Tedavisinde Devrim<\/h2>\n<p>Akero Therapeutics sadece ba\u015fka bir biyoteknoloji \u015firketi de\u011fil &#8211; MASH kaynakl\u0131 karaci\u011fer sirozunu ger\u00e7ekten tersine \u00e7evirebilen ilk tedaviyi \u00f6nc\u00fcl\u00fck ediyorlar. Lider ila\u00e7lar\u0131 efruksifermin (EFX), hepatolojide paradigma de\u011fi\u015fimi temsil ediyor.<\/p>\n<p>\u015eirket, telafi edilmi\u015f sirozun %39 oran\u0131nda tersine \u00e7evrildi\u011fini g\u00f6steren \u00e7\u0131\u011f\u0131r a\u00e7an SYMMETRY deneme sonu\u00e7lar\u0131yla MASH tedavisi konusundaki tart\u0131\u015fmalara hakim durumda &#8211; daha \u00f6nce imkans\u0131z oldu\u011fu d\u00fc\u015f\u00fcn\u00fclen bir \u015fey.<\/p>\n<p><strong>2025 E\u011flenceli Bilgi<\/strong>: Akero&#8217;nun ara\u015ft\u0131rma ekibi, ila\u00e7lar\u0131n\u0131n o kadar etkili oldu\u011funu ke\u015ffetti ki, mevcut karaci\u011fer fibrozis skorlama sistemleri hastalarda g\u00f6r\u00fclen dramatik iyile\u015fmeleri yakalayamad\u0131\u011f\u0131 i\u00e7in yeni \u00f6l\u00e7\u00fcm standartlar\u0131 geli\u015ftirmek zorunda kald\u0131lar!<\/p>\n"},"faq":[{"question":"Akero Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Akero Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden AKRO hisselerini sat\u0131n alabilirsiniz."},{"question":"AKRO hisselerinin 2025 sonu fiyat hedefi nedir?","answer":"Analistlerin 2025 y\u0131l sonu i\u00e7in AKRO hisseleri fiyat hedefi 65-70 $ aral\u0131\u011f\u0131ndad\u0131r, bu da yakla\u015f\u0131k %32-42 aras\u0131nda bir y\u00fckseli\u015f potansiyeli anlam\u0131na gelir."},{"question":"Akero Therapeutics'in FDA onayl\u0131 ilac\u0131 nedir?","answer":"Akero Therapeutics'in FDA taraf\u0131ndan onaylanan ilac\u0131 efruksifermin (EFX) olup, MASH karaci\u011fer hastal\u0131\u011f\u0131n\u0131n tedavisinde kullan\u0131lmaktad\u0131r."},{"question":"AKRO hisseleri i\u00e7in temel riskler nelerdir?","answer":"Temel riskler aras\u0131nda klinik denemelerin ba\u015far\u0131s\u0131na ba\u011fl\u0131l\u0131k, y\u00fcksek nakit t\u00fcketimi, artan rekabet ve hisse fiyat\u0131ndaki volatilite bulunmaktad\u0131r."},{"question":"Yeni ba\u015flayanlar AKRO hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Yeni ba\u015flayanlar portf\u00f6ylerinin %5-10'unu ay\u0131rmal\u0131, dolar maliyet ortalamas\u0131 yapmal\u0131, stop-loss kullanmal\u0131 ve \u00f6nemli tarihleri takip etmelidir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Akero Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Akero Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden AKRO hisselerini sat\u0131n alabilirsiniz."},{"question":"AKRO hisselerinin 2025 sonu fiyat hedefi nedir?","answer":"Analistlerin 2025 y\u0131l sonu i\u00e7in AKRO hisseleri fiyat hedefi 65-70 $ aral\u0131\u011f\u0131ndad\u0131r, bu da yakla\u015f\u0131k %32-42 aras\u0131nda bir y\u00fckseli\u015f potansiyeli anlam\u0131na gelir."},{"question":"Akero Therapeutics'in FDA onayl\u0131 ilac\u0131 nedir?","answer":"Akero Therapeutics'in FDA taraf\u0131ndan onaylanan ilac\u0131 efruksifermin (EFX) olup, MASH karaci\u011fer hastal\u0131\u011f\u0131n\u0131n tedavisinde kullan\u0131lmaktad\u0131r."},{"question":"AKRO hisseleri i\u00e7in temel riskler nelerdir?","answer":"Temel riskler aras\u0131nda klinik denemelerin ba\u015far\u0131s\u0131na ba\u011fl\u0131l\u0131k, y\u00fcksek nakit t\u00fcketimi, artan rekabet ve hisse fiyat\u0131ndaki volatilite bulunmaktad\u0131r."},{"question":"Yeni ba\u015flayanlar AKRO hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Yeni ba\u015flayanlar portf\u00f6ylerinin %5-10'unu ay\u0131rmal\u0131, dolar maliyet ortalamas\u0131 yapmal\u0131, stop-loss kullanmal\u0131 ve \u00f6nemli tarihleri takip etmelidir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Akero Therapeutics, Inc. (AKRO) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Akero Therapeutics, Inc. (AKRO) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T11:18:01+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Akero Therapeutics, Inc. (AKRO) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T11:18:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/\",\"name\":\"Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Akero Therapeutics, Inc. (AKRO) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"datePublished\":\"2025-08-25T11:18:01+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Akero Therapeutics, Inc. (AKRO) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Akero Therapeutics, Inc. (AKRO) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Akero Therapeutics, Inc. (AKRO) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T11:18:01+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Akero Therapeutics, Inc. (AKRO) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T11:18:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/","name":"Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Akero Therapeutics, Inc. (AKRO) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","datePublished":"2025-08-25T11:18:01+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-akero-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Akero Therapeutics, Inc. (AKRO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Akero Therapeutics, Inc. (AKRO) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":347229,"slug":"how-to-buy-akero-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Akero Therapeutics, Inc. (AKRO)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-akero-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":347226,"slug":"how-to-buy-akero-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Akero Therapeutics, Inc. (AKRO) - Investimento em a\u00e7\u00f5es da Akero Therapeutics, Inc. (AKRO)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-akero-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/347228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=347228"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/347228\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334009"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=347228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=347228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=347228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}